Athenex, Inc.

OTCPK:ATNX.Q Stock Report

Market Cap: US$131.7k

Athenex (ATNX.Q) Stock Overview

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. More details

ATNX.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Risk Analysis

Does not have a meaningful market cap ($132K)

Negative shareholders equity

Highly volatile share price over the past 3 months

Earnings have declined by 7.6% per year over past 5 years

+ 1 more risk

ATNX.Q Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Athenex, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Athenex
Historical stock prices
Current Share PriceUS$0.015
52 Week HighUS$6.00
52 Week LowUS$0.0003
Beta0.79
1 Month Change52.00%
3 Month Change-86.19%
1 Year Change-99.72%
3 Year Change-99.99%
5 Year Change-99.99%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Athenex prices $30M in stock and warrants offering

Aug 11

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Aug 05

Athenex GAAP EPS, revenue misses estimates

Jul 28

Athenex to sell its China API business for $19M

Jul 11

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Aug 31

Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Apr 04
Is Athenex (NASDAQ:ATNX) Weighed On By Its Debt Load?

Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

Mar 09
Have Insiders Sold Athenex, Inc. (NASDAQ:ATNX) Shares Recently?

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06
These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19
Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29
When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Shareholder Returns

ATNX.QUS BiotechsUS Market
7D0%1.5%2.9%
1Y-99.7%-10.8%13.9%

Return vs Industry: ATNX.Q underperformed the US Biotechs industry which returned -3.5% over the past year.

Return vs Market: ATNX.Q underperformed the US Market which returned 15.2% over the past year.

Price Volatility

Is ATNX.Q's price volatile compared to industry and market?
ATNX.Q volatility
ATNX.Q Average Weekly Movement339.2%
Biotechs Industry Average Movement12.1%
Market Average Movement7.7%
10% most volatile stocks in US Market17.6%
10% least volatile stocks in US Market4.0%

Stable Share Price: ATNX.Q's share price has been volatile over the past 3 months.

Volatility Over Time: ATNX.Q's weekly volatility has increased from 167% to 339% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2003275Johnson Lauwww.athenex.com

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company’s Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer.

Athenex, Inc. Fundamentals Summary

How do Athenex's earnings and revenue compare to its market cap?
ATNX.Q fundamental statistics
Market capUS$131.68k
Earnings (TTM)-US$97.98m
Revenue (TTM)US$102.82m
0.0x
P/S Ratio
0.0x
P/E Ratio

Is ATNX.Q overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATNX.Q income statement (TTM)
RevenueUS$102.82m
Cost of RevenueUS$76.12m
Gross ProfitUS$26.70m
Other ExpensesUS$124.68m
Earnings-US$97.98m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-11.31
Gross Margin25.97%
Net Profit Margin-95.29%
Debt/Equity Ratio-511.7%

How did ATNX.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/04 05:09
End of Day Share Price 2023/10/02 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Athenex, Inc. is covered by 12 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ying ShaoCredit Suisse
Jack HuDeutsche Bank
Umer RaffatEvercore ISI